The continued climb of the U.S. dollar weighed heavily on pharmaceutical giant Johnson & Johnson’s first quarter earnings reported Tuesday morning. It was in many ways a repeat of a quarter earlier — only this time the numbers were worse with currency woes cutting further into international sales, profitability and now the company’s outlook on the coming […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
The U.S. Senate, following last month’s bipartisan action by the U.S. House of Representatives, tonight overwhelmingly passed a repeal of Medicare’s controversial sustainable growth rate formula. The vote, by a whopping 92-8 vote in the Senate, will avert a 21 percent cut in Medicare payments to doctors while at the same time moving future reimbursement […]
Italian billionaire Stefano Pessina wasn’t ready this week to say Walgreens Boots Alliance (WBA) was prepared to buy Rite Aid (RAD), but he said more government influence on payments to pharmacies could spur rapid consolidation in the U.S. Now the top executive at Walgreens, Pessina speaks from experience having run Alliance Boots pharmacies in Europe […]
Large-scale health data breaches reported by doctors and health plans have been rising steadily, a new report shows. From 2010 to 2013, nearly 1000 large breaches affected more than 29 million individual health records, and more than half resulted from theft or loss of laptops, thumb drives and paper records, according to researchers with access […]
April 14, 2015By Riley McDermid, BioSpace.com Breaking News Sr. Editor The American biotech sector will see a continued boom in its merger and acquisition cycle after an unprecedented first quarter saw over $100 billion in deals, with companies like Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG), and Biogen, Inc. all poised to participate, said UBS […]
April 14, 2015By Alex Keown, BioSpace.com Breaking News Staff MELVILLE, N.Y.– BioRestorative Therapies, Inc. a life sciences company developing adult stem cell-based therapies for various medical applications, moved its corporate and laboratory operations to Long Island from Jupiter, Fla., the company announced this morning. In 2014 BioRestorative Therapies (BRT) was awarded $500,000 in tax credits […]
April 14, 2015By Mark Terry, BioSpace.com Breaking News Staff Kenilworth, N.J.-based Merck & Co. (MRK)’s recent Securities and Exchange Commission (SEC) filings indicate that CEO Kenneth Frazier will see an increase in total compensation of about 87 percent this year. In addition, Robert Davis, company chief financial officer, will see an increase of about 10 […]
April 14, 2015By Krystle Vermes, BioSpace.com Breaking News Staff Delaware-based Incyte Corporation (INCY), an oncology-focused biopharmaceutical company, announced on April 14 that it will be establishing a European headquarters in Geneva, Switzerland. Incyte Europe S.a.r.l., as it has been titled, will conduct European clinical development operations. It will occupy approximately 9,000 square feet by mid-2015. […]
NEW YORK, April 14, 2015 /PRNewswire/ — The CementBloc has announced the addition of Robin Tzannes, Sharon Howard-Butler, and Marc Law to its creative leadership team. Photo – http://photos.prnewswire.com/prnh/20150414/198603 Sharon Howard-Butler and Marc Law, formerly of Saatchi & Saatchi Health Sydney, join the agency as SVP, Creative Director, Copy, and VP, Associate Creative Director, Art, respectively. […]
REGiMMUNE Announces Collaboration With JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells
Antigen-Specific Immunotherapy to Potentially Prevent or Delay Diabetes in Preclinical Model TOKYO, JAPAN–(Marketwired – Apr 14, 2015) – REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a research collaboration to develop an antigen-specific immunotherapy utilizing RGI’s proprietary αGalCer/liposome platform for immunological tolerance for […]